Thomas Woiwode - 12 May 2021 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Role
Director
Signature
Thomas Woiwode, by /s/ Ron A. Metzger, Attorney-in-Fact
Issuer symbol
ADVM
Transactions as of
12 May 2021
Net transactions value
$0
Form type
4
Filing time
14 May 2021, 20:05:38 UTC
Next filing
28 May 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADVM Stock Option (Right to Buy) Award $0 +40,000 $0.000000 40,000 12 May 2021 Common Stock 40,000 $3.70 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option will vest on the earlier of May 12, 2022 or the 2022 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date.